Use of hecate-chorionic gonadotropin β conjugate in therapy of lutenizing hormone receptor expressing gonadal somatic cell tumors

Molecular and Cellular Endocrinology

Volumn 269, Issue 1-2 SPEC. ISS., 2007, Pages 17-25

  Rivero Muller A ^a   Vuorenoja, S ^a   Tuominen, M ^a   Waclawik A ^b   Brokken, L J S ^a   Ziecik, A J ^b   Huhtaniemi, I ^a,c   Rahman, N A ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b INSTITUTE OF ANIMAL REPRODUCTION AND FOOD RESEARCH   (Poland)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Gonadal tumors; Gonadotropins; Hecate CG conjugate; LHR; Lytic peptide hecate; Transgenic mice

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; LUTEINIZING HORMONE RECEPTOR; PEPTIDE; PEPTIDE HECATE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CYTOTOXICITY; GENE TARGETING; GONADAL CELL TUMOR; HUMAN; LIGAND BINDING; MEDICAL RESEARCH; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; XENOGRAFT;

ANIMALS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DRUG DELIVERY SYSTEMS; FEMALE; GENE THERAPY; HUMANS; MALE; MELITTEN; MODELS, BIOLOGICAL; OVARIAN NEOPLASMS; RECEPTORS, LH; TESTICULAR NEOPLASMS;

EID: 33947574542     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2006.11.016     Document Type: Review

References (64)

1. Auersperg N., Wong A.S., Choi K.C., Kang S.K., and Leung P.C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 22 (2001) 255-288
2. Bodek G., Vierre S., Rivero-Muller A., Huhtaniemi I., Ziecik A.J., and Rahman N.A. A novel targeted therapy of Leydig and granulosa cell tumors through the luteinizing hormone receptor using a hecate-chorionic gonadotropin beta conjugate in transgenic mice. Neoplasia 7 (2005) 497-508
3. Bohdiewicz P.J. Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging. J. Nucl. Med. Technol. 26 (1998) 155-163 (quiz 170-171)
4. Boman H.G. Peptide antibiotics and their role in innate immunity. Annu. Rev. Immunol. 13 (1995) 61-92
5. Burek C., Burek M., Roth J., and Los M. Calcium induces apoptosis and necrosis in hematopoetic malignant cells: evidence of caspase-8 dependent and FADD-autonomous pathway. Gene Ther. Mol. Biol. (2003) 173-179
6. Chawla-Sarkar M., Bae S.I., Reu F.J., Jacobs B.S., Lindner D.J., and Borden E.C. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 11 (2004) 915-923
7. Crayford T.J., Campbell S., Bourne T.H., Rawson H.J., and Collins W.P. Benign ovarian cysts and ovarian cancer: a cohort study with implications for screening. Lancet 355 (2000) 1060-1063
8. Cronje H.S., Niemand I., Bam R.H., and Woodruff J.D. Review of the granulosa-theca cell tumors from the emil Novak ovarian tumor registry. Am. J. Obstet. Gynecol. 180 (1999) 323-327
9. Gawronska B., Paukku T., Huhtaniemi I., Wasowicz G., and Ziecik A.J. Oestrogen-dependent expression of LH/hCG receptors in pig Fallopian tube and their role in relaxation of the oviduct. J. Reprod. Fertil. 115 (1999) 293-301
10. Gawronska B., Leuschner C., Enright F.M., and Hansel W. Effects of a lytic peptide conjugated to beta HCG on ovarian cancer: studies in vitro and in vivo. Gynecol. Oncol. 85 (2002) 45-52
11. Gaya A.M., and Rustin G.J. Vascular disrupting agents: a new class of drug in cancer therapy. Clin. Oncol. (Roy. Coll. Radiol.) 17 (2005) 277-290
12. Goff B.A., Mandel L., Muntz H.G., and Melancon C.H. Ovarian carcinoma diagnosis. Cancer 89 (2000) 2068-2075
13. Hacein-Bey-Abina S., Fischer A., and Cavazzana-Calvo M. Gene therapy of X-linked severe combined immunodeficiency. Int. J. Hematol. 76 (2002) 295-298
14. Hacein-Bey-Abina S., Le Deist F., Carlier F., Bouneaud C., Hue C., De Villartay J.P., Thrasher A.J., Wulffraat N., Sorensen R., Dupuis-Girod S., Fischer A., Davies E.G., Kuis W., Leiva L., and Cavazzana-Calvo M. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. New Engl. J. Med. 346 (2002) 1185-1193
15. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., Lim A., Osborne C.S., Pawliuk R., Morillon E., Sorensen R., Forster A., Fraser P., Cohen J.I., de Saint Basile G., Alexander I., Wintergerst U., Frebourg T., Aurias A., Stoppa-Lyonnet D., Romana S., Radford-Weiss I., Gross F., Valensi F., Delabesse E., Macintyre E., Sigaux F., Soulier J., Leiva L.E., Wissler M., Prinz C., Rabbitts T.H., Le Deist F., Fischer A., and Cavazzana-Calvo M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 (2003) 415-419
16. Halin C., Niesner U., Villani M.E., Zardi L., and Neri D. Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins. Int. J. Cancer 102 (2002) 109-116
17. Halpern S.E., Hagan P.L., Garver P.R., Koziol J.A., Chen A.W., Frincke J.M., Bartholomew R.M., David G.S., and Adams T.H. Stability, characterization, and kinetics of 111In-labeled monoclonal antitumor antibodies in normal animals and nude mouse-human tumor models. Cancer Res. 43 (1983) 5347-5355
18. Hansel W., Leuschner C., Gawronska B., and Enright F. Targeted destruction of prostate cancer cells and xenografts by lytic peptide-betaLH conjugates. Reprod. Biol. 1 (2001) 20-32
19. Henk W.G., Todd W.J., Enright F.M., and Mitchell P.S. The morphological effects of two antimicrobial peptides, hecate-1 and melittin, on Escherichia coli. Scanning Microsc. 9 (1995) 501-507
20. Hertler A.A., and Frankel A.E. Immunotoxins: a clinical review of their use in the treatment of malignancies. J. Clin. Oncol. 7 (1989) 1932-1942
21. Jaattela M. Escaping cell death: survival proteins in cancer. Exp. Cell Res. 248 (1999) 30-43
22. Kakinuma C., Takagaki K., Yatomi T., Nakamura N., Nagata S., Uemura A., and Shibutani Y. Acute toxicity of an anti-Fas antibody in mice. Toxicol. Pathol. 27 (1999) 412-420
23. Kananen K., Markkula M., Rainio E., Su J.G., Hsueh A.J., and Huhtaniemi I.T. Gonadal tumorigenesis in transgenic mice bearing the mouse inhibin alpha-subunit promoter/simian virus T-antigen fusion gene: characterization of ovarian tumors and establishment of gonadotropin-responsive granulosa cell lines. Mol. Endocrinol. 9 (1995) 616-627
24. Kananen K., Markkula M., El-Hefnawy T., Zhang F.P., Paukku T., Su J.G., Hsueh A.J., and Huhtaniemi I. The mouse inhibin alpha-subunit promoter directs SV40 T-antigen to Leydig cells in transgenic mice. Mol. Cell. Endocrinol. 119 (1996) 135-146
25. Kasahara N., Dozy A.M., and Kan Y.W. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266 (1994) 1373-1376
26. Kinkade S. Testicular cancer. Am. Fam. Physician 59 (1999) 2539-2544, 2549-2550
27. Kohler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975) 495-497
28. Konishi I., Kuroda H., and Mandai M. Review: gonadotropins and development of ovarian cancer. Oncology 57 Suppl. 2 (1999) 45-48
29. Kuroda H., Mandai M., Konishi I., Tsuruta Y., Kusakari T., Kariya M., and Fujii S. Human ovarian surface epithelial (OSE) cells express LH/hCG receptors, and hCG inhibits apoptosis of OSE cells via up-regulation of insulin-like growth factor-1. Int. J. Cancer 91 (2001) 309-315
30. Lawrence D., Shahrokh Z., Marsters S., Achilles K., Shih D., Mounho B., Hillan K., Totpal K., DeForge L., Schow P., Hooley J., Sherwood S., Pai R., Leung S., Khan L., Gliniak B., Bussiere J., Smith C.A., Strom S.S., Kelley S., Fox J.A., Thomas D., and Ashkenazi A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 7 (2001) 383-385
31. Leuschner C., and Hansel W. Membrane disrupting lytic peptides for cancer treatments. Curr. Pharm. Des. 10 (2004) 2299-2310
32. Leuschner C., Enright F.M., Melrose P.A., and Hansel W. Targeted destruction of androgen-sensitive and -insensitive prostate cancer cells and xenografts through luteinizing hormone receptors. Prostate 46 (2001) 116-125
33. Leuschner C., Enright F.M., Gawronska-Kozak B., and Hansel W. Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors. Prostate 56 (2003) 239-249
34. Leuschner C., Enright F.M., Gawronska B., and Hansel W. Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivo. Breast Cancer Res. Treat. 78 (2003) 17-27
35. Lin Y., Choksi S., Shen H.M., Yang Q.F., Hur G.M., Kim Y.S., Tran J.H., Nedospasov S.A., and Liu Z.G. Tumor necrosis factor-induced non-apoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation. J. Biol. Chem. 279 (2004) 10822-10828
36. Los M., Mozoluk M., Ferrari D., Stepczynska A., Stroh C., Renz A., Herceg Z., Wang Z.Q., and Schulze-Osthoff K. Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling. Mol. Biol. Cell 13 (2002) 978-988
37. Los M., Burek C.J., Stroh C., Benedyk K., Hug H., and Mackiewicz A. Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design. Drug Discov. Today 8 (2003) 67-77
38. Lu J.J., Zheng Y., Kang X., Yuan J.M., Lauchlan S.C., Pike M.C., and Zheng W. Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer. Gynecol. Oncol. 79 (2000) 158-168
39. Mandai M., Konishi I., Kuroda H., Fukumoto M., Komatsu T., Yamamoto S., Nanbu K., Rao C.V., and Mori T. Messenger ribonucleic acid expression of LH/hCG receptor gene in human ovarian carcinomas. Eur. J. Cancer 33 (1997) 1501-1507
40. Matsuzaki K. Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochim. Biophys. Acta 1462 (1999) 1-10
41. Meduri G., Charnaux N., Loosfelt H., Jolivet A., Spyratos F., Brailly S., and Milgrom E. Luteinizing hormone/human chorionic gonadotropin receptors in breast cancer. Cancer Res. 57 (1997) 857-864
42. Morbeck D.E., Roche P.C., Keutmann H.T., and McCormick D.J. A receptor binding site identified in the region 81-95 of the beta-subunit of human luteinizing hormone (LH) and chorionic gonadotropin (hCG). Mol. Cell. Endocrinol. 97 (1993) 173-181
43. Nomura T., Yamasaki M., Nomura Y., and Mimata H. Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. Oncol. Rep. 14 (2005) 993-997
44. Oren Z., Hong J., and Shai Y. A repertoire of novel antibacterial diastereomeric peptides with selective cytolytic activity. J. Biol. Chem. 272 (1997) 14643-14649
45. Papo N., and Shai Y. New lytic peptides based on the d,l-amphipathic helix motif preferentially kill tumor cells compared to normal cells. Biochemistry 42 (2003) 9346-9354
46. Papo N., Shahar M., Eisenbach L., and Shai Y. A novel lytic peptide composed of dl-amino acids selectively kills cancer cells in culture and in mice. J. Biol. Chem. 278 (2003) 21018-21023
47. Pastan I., and FitzGerald D. Recombinant toxins for cancer treatment. Science 254 (1991) 1173-1177
48. Peck-Miller K.A., Darveau R.P., and Fell H.P. Identification of serum components that inhibit the tumoricidal activity of amphiphilic alpha helical peptides. Cancer Chemother. Pharmacol. 32 (1993) 109-115
49. Pimm M.V., Perkins A.C., and Baldwin R.W. Differences in tumour and normal tissue concentrations of iodine- and indium-labelled monoclonal antibody. II. Biodistribution studies in mice with human tumour xenografts. Eur. J. Nucl. Med. 11 (1985) 300-304
50. Rahman N.A., and Huhtaniemi I.T. Ovarian tumorigenesis in mice transgenic for murine inhibin alpha subunit promoter-driven Simian Virus 40 T-antigen: ontogeny, functional characteristics, and endocrine effects. Biol. Reprod. 64 (2001) 1122-1130
51. Rao Ch V., Zhou X.L., and Lei Z.M. Functional luteinizing hormone/chorionic gonadotropin receptors in human adrenal cortical H295R cells. Biol. Reprod. 71 (2004) 579-587
52. Rosal R., Brandt-Rauf P., Pincus M.R., Wang H., Mao Y., Li Y., and Fine R.L. The role of alpha-helical structure in p53 peptides as a determinant for their mechanism of cell death: necrosis versus apoptosis. Adv. Drug Deliv. Rev. 57 (2005) 653-660
53. Shai Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim. Biophys. Acta 1462 (1999) 55-70
54. Sharpless N.E., and Depinho R.A. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat. Rev. Drug Discov. 5 (2006) 741-754
55. Suggitt M., and Bibby M.C. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin. Cancer Res. 11 (2005) 971-981
56. Tao Y.X., Bao S., Ackermann D.M., Lei Z.M., and Rao C.V. Expression of luteinizing hormone/human chorionic gonadotropin receptor gene in benign prostatic hyperplasia and in prostate carcinoma in humans. Biol. Reprod. 56 (1997) 67-72
57. Timmer T., de Vries E.G., and de Jong S. Fas receptor-mediated apoptosis: a clinical application?. J. Pathol. 196 (2002) 125-134
58. Utsugi T., Schroit A.J., Connor J., Bucana C.D., and Fidler I.J. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 51 (1991) 3062-3066
59. Vanderhyden B.C., Shaw T.J., and Ethier J.F. Animal models of ovarian cancer. Reprod. Biol. Endocrinol. 1 (2003) 67
60. Yeh M.Y., Roffler S.R., and Yu M.H. Doxorubicin: monoclonal antibody conjugate for therapy of human cervical carcinoma. Int. J. Cancer 51 (1992) 274-282
61. Yoon T.K., Shichinohe T., Laquerre S., and Kasahara N. Selectively replicating adenoviruses for oncolytic therapy. Curr. Cancer Drug Targets 1 (2001) 85-107
62. Young R.H., Dickersin G.R., and Scully R.E. Juvenile granulosa cell tumor of the ovary. A clinicopathological analysis of 125 cases. Am. J. Surg. Pathol. 8 (1984) 575-596
63. Zaleska M., Bodek G., Jana B., Hansel W., and Ziecik A.J. Targeted destruction of normal and cancer cells through lutropin/choriogonadotropin receptors using hecate-betaCG conjugate. Exp. Clin. Endocrinol. Diabetes 111 (2003) 146-153
64. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 415 (2002) 389-395